Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Chiral Resolution . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN108409615B discloses a green route for chiral sulfinamides, eliminating liquid ammonia usage and enhancing yield for reliable pharmaceutical intermediate supply chains.
Innovative synthesis eliminates chiral chromatography steps enhancing purity above 99.8 HPLC while reducing production costs through simplified manufacturing workflow.
This patent introduces a streamlined three-step synthesis eliminating dual chiral chromatography, enhancing purity and reducing supply chain complexity for pharma intermediates.
Reduce production costs and environmental impact with >98% ee and 92% yield in asymmetric synthesis of key florfenicol intermediate for pharmaceutical manufacturing.
Solve complex synthesis challenges with this 5-step chiral resolution method. Eliminate corrosive reagents, reduce equipment costs, and ensure 99%+ purity for your pharmaceutical intermediates.
Solve chiral purity challenges in halichondrin synthesis with 99.7% ee and 92% yield. Reduce impurity removal burden for Eribulin mesylate production. CDMO expertise for scalable manufacturing.
Solve chiral purity challenges in halichondrin synthesis. Our CDMO expertise delivers >99% ee intermediates with 92% yield, reducing impurity risks for oncology drug development.
Overcome chiral resolution challenges in Niraparib manufacturing. New metal-free synthesis achieves 97.51% purity with 26.75% overall yield. Reduce equipment costs and supply chain risks.
Discover how chiral phosphoric acid catalysis enables high-yield, enantioselective synthesis of axial chiral aryl indoles for cancer drug development and supply chain de-risking.
Eliminate chiral column costs with novel crystallization-based resolution. Achieve >99% ee and 76-78% yield for 6,6'-dihydroxy-5,5'-bisquinoline. Scale to 100MT/yr with NINGBO INNO PHARMCHEM's CDMO expertise.
Discover a chiral resolution-free synthesis for moxifloxacin with high yield and purity. Reduce production costs and supply chain risks for your API manufacturing.
Solve high-cost synthesis challenges for Brivaracetam intermediates. New 5-step route with 78% yield reduces raw material costs by 40%—ideal for R&D and procurement teams.
Solve high-cost chiral separation for Abacavir synthesis. 30% yield boost, 40% cost reduction. Scale to 100MT/yr with >99% purity.
Solve chiral resolution challenges in avacopan synthesis with 63.59% yield and 98.8% ee. Reduce costs and scale efficiently for clinical and commercial supply.